AbCellera Biologics: Potentially Bottoming Out Amidst Terrible Market SentimentSeeking Alpha • 04/22/22
Abcellera Biologics, Inc. (ABCL) CEO Carl Hansen on Q4 2021 Earnings Call TranscriptSeeking Alpha • 02/25/22
AbCellera to Participate Virtually in the Truist Securities AI Symposium – Biotech & ToolsBusiness Wire • 02/23/22
AbCellera to Present Virtually at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022Business Wire • 02/11/22
AbCellera-Discovered Antibody, Bebtelovimab, Receives U.S. FDA Emergency Use Authorization for the Treatment of Mild-to-Moderate COVID-19Business Wire • 02/11/22
AbCellera Biologics: Bebtelovimab Supply Deal Provides A Much Needed Shot In The ArmSeeking Alpha • 02/11/22
Lilly to Supply up to 600,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 TreatmentsBusiness Wire • 02/11/22
AbCellera Biologics: Potentially Worth Over $41 Currently, Without COVID RevenuesSeeking Alpha • 12/05/21
AbCellera-Discovered Bamlanivimab Together with Etesevimab Authorized as the First and Only Antibody Therapy for Emergency Use in COVID-19 Patients Under the Age of 12Business Wire • 12/03/21
AbCellera Announces the Appointment of Neil Aubuchon as Chief Commercial OfficerBusiness Wire • 12/02/21
Abcellera Biologics, Inc. (ABCL) CEO Carl Hansen on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/10/21
How Much Upside is Left in AbCellera Biologics Inc. (ABCL)? Wall Street Analysts Think 161%Zacks Investment Research • 11/05/21
AbCellera Announces Virtual Presentations at Investor Conferences in NovemberBusiness Wire • 11/04/21
Lilly to Supply 614,000 Additional Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab to the U.S. Government for the Treatment or Post-Exposure Prevention of COVID-19Business Wire • 11/02/21
AbCellera Biologics: The COVID Premium Is Gone, Thanks To Merck - Time To BuySeeking Alpha • 10/18/21